Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes
- Resource Type
- Article
- Authors
- Thach, Andrew; Zichlin, Miriam L; Kirson, Noam; Yang, Karen; Gaburo, Katherine; Pappert, Eric; Mehta, Darshan; Williams, G Rhys
- Source
- Journal of Comparative Effectiveness Research; January 2022, Vol. 11 Issue: 4 p285-295, 11p
- Subject
- Language
- ISSN
- 20426305; 20426313
Aim:To compare efficacy of apomorphine sublingual film (APL) and levodopa inhalation powder (CVT-301) for ‘on-demand’ treatment of Parkinson's disease ‘OFF’ episodes. Patients & methods:Patient-level data from an APL pivotal study were re-weighted to match average baseline characteristics from a CVT-301 study (SPAN-PD). Placebo-adjusted treatments were compared at week 12. Results:Improvements in predose Unified Parkinson's Disease Rating Scale Part III scores were significantly larger for APL versus CVT-301 at 60 min postdose (least squares mean difference-in-difference: -8.82; p = 0.002); difference at 30 min favored APL but was not statistically significant (-4.46; p = 0.103). Total daily ‘OFF’ time reductions were significantly larger for APL versus CVT-301 (-1.31 h; p = 0.013). Conclusion:Results suggest APL treatment may lead to improved efficacy versus CVT-301.